The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1836-1846

  Zhang, Ying ^a   Ertl, Hildegund C J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN D; MELANOMA ANTIGEN; MELANOMA VACCINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG POTENCY; EXPRESSION VECTOR; FEMALE; HERPES SIMPLEX VIRUS; IMMUNOGENICITY; MELANOMA; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHEMOTHERAPY, ADJUVANT; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMAGGLUTININS, VIRAL; HERPESVIRUS 1, HUMAN; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; VIRAL ENVELOPE PROTEINS;

EID: 84905963027     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302029     Document Type: Article

References (51)

1. Mittendorf, E. A. , and P. Sharma. 2010. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev. Vaccines 9: 89-105.
2. Finn, O. J. 2003. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641.
3. Haile, S. T. , J. J. Bosch, N. I. Agu, A. M. Zeender, P. Somasundaram, M. K. Srivastava, S. Britting, J. B. Wolf, B. R. Ksander, and S. Ostrand-Rosenberg. 2011. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J. Immunol. 186: 6822-6829.
4. Jacobs, J. F. , S. Nierkens, C. G. Figdor, I. J. de Vries, and G. J. Adema. 2012. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 13: e32-e42.
5. Umansky, V. , and A. Sevko. 2012. Melanoma-induced immunosuppression and its neutralization. Semin. Cancer Biol. 22: 319-326.
6. Izawa, S. , K. Mimura, M. Watanabe, T. Maruyama, Y. Kawaguchi, H. Fujii, and K. Kono. 2013. Increased prevalence of tumor-infiltrating regulatory T cells is closely related to their lower sensitivity to H2O2-induced apoptosis in gastric and esophageal cancer. Cancer Immunol. Immunother. 62: 161-170.
7. Lipson, E. J. 2013. Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. OncoImmunology 2: e23661.
8. Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264.
9. Callahan, M. K. , M. A. Postow, and J. D. Wolchok. 2013. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin. Dermatol. 31: 191-199.
10. Duraiswamy, J. , K. M. Kaluza, G. J. Freeman, and G. Coukos. 2013. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73: 3591-3603.
11. Intlekofer, A. M. , and C. B. Thompson. 2013. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94: 25-39.
12. Whitbeck, J. C. , C. Peng, H. Lou, R. Xu, S. H. Willis, M. Ponce de Leon, T. Peng, A. V. Nicola, R. I. Montgomery, M. S. Warner, et al. 1997. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J. Virol. 71: 6083-6093.
13. Steinberg, M. W. , T. C. Cheung, and C. F. Ware. 2011. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244: 169-187.
14. Cai, G. , and G. J. Freeman. 2009. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229: 244-258.
15. Stiles, K. M. , J. C. Whitbeck, H. Lou, G. H. Cohen, R. J. Eisenberg, and C. Krummenacher. 2010. Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition. J. Virol. 84: 11646-11660.
16. Lasaro, M. O. , N. Tatsis, S. E. Hensley, J. C. Whitbeck, S. -W. Lin, J. J. Rux, E. J. Wherry, G. H. Cohen, R. J. Eisenberg, and H. C. Ertl. 2008. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med. 14: 205-212.
17. DiMenna, L. , B. Latimer, E. Parzych, L. H. Haut, K. Töpfer, S. Abdulla, H. Yu, B. Manson, W. Giles-Davis, D. Zhou, et al. 2010. Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. J. Immunol. 184: 5475-5484.
18. Lasaro, M. O. , M. Sazanovich, W. Giles-Davis, P. Mrass, R. M. Bunte, D. A. Sewell, S. F. Hussain, Y. -X. Fu, W. Weninger, Y. Paterson, and H. C. Ertl. 2011. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol. Ther. 19: 1727-1736.
19. Bacik, I. , J. H. Cox, R. Anderson, J. W. Yewdell, and J. R. Bennink. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide. J. Immunol. 152: 381-387.
20. Kianizad, K. , L. A. Marshall, N. Grinshtein, D. Bernard, R. Margl, S. Cheng, F. Beermann, Y. Wan, and J. Bramson. 2007. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res. 67: 6459-6467.
21. Alexander, J. , J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Sette, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751-761.
22. Guevara-Patino, J. A. , M. E. Engelhorn, M. J. Turk, C. Liu, F. Duan, G. Rizzuto, A. D. Cohen, T. Merghoub, J. D. Wolchok, and A. N. Houghton. 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 116: 1382-1390.
23. Bergmann, C. C. , Q. Yao, C. K. Ho, and S. L. Buckwold. 1996. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol. 157: 3242-3249.
24. Del Val, M. , H. -J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H. Koszinowski. 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66: 1145-1153.
25. Zhou, D. , X. Zhou, A. Bian, H. Li, H. Chen, J. C. Small, Y. Li, W. Giles-Davis, Z. Xiang, and H. C. J. Ertl. 2010. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat. Protoc. 5: 1775-1785.
26. Wherry, E. J. , J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927.
27. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
28. Sharpe, A. H. 2009. Mechanisms of costimulation. Immunol. Rev. 229: 5-11.
29. de Vries, I. J. M. 2013. The nature of activatory and tolerogenic dendritic cellderived signal II. Front. Immunol. 4 53
30. Han, P. , O. D. Goularte, K. Rufner, B. Wilkinson, and J. Kaye. 2004. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J. Immunol. 172: 5931-5939.
31. Riley, J. L. 2009. PD-1 signaling in primary T cells. Immunol. Rev. 229: 114-125.
32. Parry, R. V. , J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
33. Hemmings, B. A. , and D. F. Restuccia. 2012. PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol. 4: a011189-a011189.
34. Gavrieli, M. , N. Watanabe, S. K. Loftin, T. L. Murphy, and K. M. Murphy. 2003. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312: 1236-1243.
35. Ananthakrishnan, A. N. , E. C. Oxford, D. D. Nguyen, J. Sauk, V. Yajnik, and R. J. Xavier. 2013. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment Pharmacol. Ther. 38: 522-530.
36. Chadha, S. , K. Miller, L. Farwell, S. Sacks, M. J. Daly, J. D. Rioux, and T. J. Vyse. 2006. Haplotype analysis of tumour necrosis factor receptor genes in 1p36: no evidence for association with systemic lupus erythematosus. Eur. J. Hum. Genet. 14: 69-78.
37. Jung, H. W. , S. J. La, J. Y. Kim, S. K. Heo, J. Y. Kim, S. Wang, K. K. Kim, K. M. Lee, H. R. Cho, H. W. Lee, et al. 2003. High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases. Exp. Mol. Med. 35: 501-508.
38. Steinberg, M. W. , O. Turovskaya, R. B. Shaikh, G. Kim, D. F. McCole, K. Pfeffer, K. M. Murphy, C. F. Ware, and M. Kronenberg. 2008. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J. Exp. Med. 205: 1463-1476.
39. del Rio, M. -L. , J. Kurtz, C. Perez-Martinez, A. Ghosh, J. A. Perez-Simon, and J. -I. Rodriguez-Barbosa. 2011. B-and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity. Transplantation 92: 1085-1093.
40. Costello, R. T. , F. Mallet, B. Barbarat, J. -M. Schiano De Colella, D. Sainty, R. W. Sweet, A. Truneh, and D. Olive. 2003. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 17: 2500-2507.
41. Derré, L. , J. -P. Rivals, C. Jandus, S. Pastor, D. Rimoldi, P. Romero, O. Michielin, D. Olive, and D. E. Speiser. 2010. BTLA mediates inhibition of human tumorspecific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120: 157-167.
42. Fourcade, J. , Z. Sun, O. Pagliano, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, D. Olive, V. Kuchroo, and H. M. Zarour. 2012. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72: 887-896.
43. Kaufmann, D. E. , and B. D. Walker. 2008. Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr. Opin. HIV AIDS 3: 362-367.
44. Dustin, L. B. , and C. M. Rice. 2007. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25: 71-99.
45. Baitsch, L. , P. Baumgaertner, E. Devêvre, S. K. Raghav, A. Legat, L. Barba, S. Wieckowski, H. Bouzourene, B. Deplancke, P. Romero, et al. 2011. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.
46. Kim, P. S. , and R. Ahmed. 2010. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22: 223-230.
47. Blackburn, S. D. , H. Shin, W. N. Haining, T. Zou, C. J. Workman, A. Polley, M. R. Betts, G. J. Freeman, D. A. A. Vignali, and E. J. Wherry. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37.
48. Wherry, E. J. , S. -J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
49. Oestreich, K. J. , H. Yoon, R. Ahmed, and J. M. Boss. 2008. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181: 4832-4839.
50. Hebeisen, M. , L. Baitsch, D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2013. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123: 1044-1056.
51. Bos, R. , K. L. Marquardt, J. Cheung, and L. A. Sherman. 2012. Functional differences between low-and high-affinity CD8+ T cells in the tumor environment. OncoImmunology 1: 1239-1247.